ADT |
Androgen-deprivation therapy |
CRPC |
Castration-resistant prostate cancer |
DMSO |
Dimethyl sulfoxide |
EGFR |
Epidermal growth factor receptors |
EMT |
Epithelial–mesenchymal transition |
EDTA |
Ethylenediaminetetraacetic acid |
FBS |
Fetal bovine serum |
FGFR |
Fibroblast growth factor receptor |
GH |
Growth hormone |
GHRH |
Growth hormone-releasing hormone |
GHRH-R |
Growth hormone-releasing hormone receptor |
GPCRs |
G protein-coupled receptors |
ICAM-1 |
Intercellular adhesion molecule-1 |
IGF-I |
Insulin-like growth factor type I |
MMPs |
Matrix metalloproteinases |
MTT |
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazole bromide |
PBS |
Phosphate-buffered saline |
PCa |
Prostate cancer |
pGHRH-R |
Pituitary-type growth hormone-releasing hormone receptor |
PI |
Propidium iodide |
RTK |
Receptor tyrosine kinase |
TBS |
Tris-buffered saline |
TKIs |
Tyrosine kinase inhibitors |
TMPS |
Triple-membrane-passing-signal |